Target Information
| Target General Infomation | Top | ||||
|---|---|---|---|---|---|
| Target ID |
T94918
|
||||
| Target Name |
COVID-19 RNA-directed RNA polymerase (RdRp)
|
||||
| Synonyms |
COVID-19 Pol; COVID-19 nsp12
|
||||
| Gene Name |
COVID-19 rep; COVID-19 1a-1b
|
||||
| Target Status |
Target in Phase 3 Trial
|
[1] | |||
| Disease | [+] 1 Target-related Diseases | + | |||
| 1 | COVID-19 [ICD-11: 1D6Y] | ||||
| Function |
Responsible for replication and transcription of the viral RNA genome.
|
||||
| BioChemical Class |
Coronaviruses polyprotein 1ab family
|
||||
| UniProt ID | |||||
| EC Number |
EC 2.7.7.48
|
||||
| Sequence |
SADAQSFLNRVCGVSAARLTPCGTGTSTDVVYRAFDIYNDKVAGFAKFLKTNCCRFQEKD
EDDNLIDSYFVVKRHTFSNYQHEETIYNLLKDCPAVAKHDFFKFRIDGDMVPHISRQRLT KYTMADLVYALRHFDEGNCDTLKEILVTYNCCDDDYFNKKDWYDFVENPDILRVYANLGE RVRQALLKTVQFCDAMRNAGIVGVLTLDNQDLNGNWYDFGDFIQTTPGSGVPVVDSYYSL LMPILTLTRALTAESHVDTDLTKPYIKWDLLKYDFTEERLKLFDRYFKYWDQTYHPNCVN CLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQDVN LHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVAALTNNVAFQTVKPGNFNKDFY DFAVSKGFFKEGSSVELKHFFFAQDGNAAISDYDYYRYNLPTMCDIRQLLFVVEVVDKYF DCYDGGCINANQVIVNNLDKSAGFPFNKWGKARLYYDSMSYEDQDALFAYTKRNVIPTIT QMNLKYAISAKNRARTVAGVSICSTMTNRQFHQKLLKSIAATRGATVVIGTSKFYGGWHN MLKTVYSDVENPHLMGWDYPKCDRAMPNMLRIMASLVLARKHTTCCSLSHRFYRLANECA QVLSEMVMCGGSLYVKPGGTSSGDATTAYANSVFNICQAVTANVNALLSTDGNKIADKYV RNLQHRLYECLYRNRDVDTDFVNEFYAYLRKHFSMMILSDDAVVCFNSTYASQGLVASIK NFKSVLYYQNNVFMSEAKCWTETDLTKGPHEFCSQHTMLVKQGDDYVYLPYPDPSRILGA GCFVDDIVKTDGTLMIERFVSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTGHML DMYSVMLTNDNTSRYWEPEFYEAMYTPHTVLQ |
||||
| Drugs and Modes of Action | Top | ||||
|---|---|---|---|---|---|
| Drugs in Phase 3 Trial | [+] 2 Drugs in Phase 3 Trial | + | |||
| 1 | Favipiravir | Drug Info | Phase 3 Trial | COVID-19 | [2], [3] |
| 2 | Remdesivir | Drug Info | Phase 3 Trial | COVID-19 | [4] |
| Drugs in Phase 2 Trial | [+] 1 Drugs in Phase 2 Trial | + | |||
| 1 | Lopinavir + ritonavir + ribavirin + interferon beta-1b | Drug Info | Phase 2 Trial | COVID-19 | [5] |
| Drugs in Phase 1 Trial | [+] 1 Drugs in Phase 1 Trial | + | |||
| 1 | Galidesivir | Drug Info | Phase 1 Trial | COVID-19 | [6] |
| Investigative agents | [+] 3 Investigative agents | + | |||
| 1 | Penciclovir | Drug Info | Investigative | COVID-19 | [7], [8] |
| 2 | Anidulafungin | Drug Info | Investigative | COVID-19 | [8] |
| 3 | Suramin | Drug Info | Investigative | COVID-19 | [8] |
| Mode of Action | [+] 2 Modes of Action | + | |||
| Inhibitor | [+] 6 Inhibitor drugs | + | |||
| 1 | Favipiravir | Drug Info | [9], [10] | ||
| 2 | Remdesivir | Drug Info | [1], [7] | ||
| 3 | Lopinavir + ritonavir + ribavirin + interferon beta-1b | Drug Info | [10] | ||
| 4 | Anidulafungin | Drug Info | [8] | ||
| 5 | Penciclovir | Drug Info | [7], [8] | ||
| 6 | Suramin | Drug Info | [8] | ||
| Blocker | [+] 1 Blocker drugs | + | |||
| 1 | Galidesivir | Drug Info | [11] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| 1 | Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. | ||||
| 2 | ClinicalTrials.gov (NCT04336904) Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19 | ||||
| 3 | ChiCTR.org.cn (ChiCTR2000030254) the Efficacy and Safety of Favipiravir for novel coronavirusinfected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study | ||||
| 4 | ClinicalTrials.gov (NCT04315948) Trial of Treatments for COVID-19 in Hospitalized Adults | ||||
| 5 | ClinicalTrials.gov (NCT04276688) Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | ||||
| 6 | ClinicalTrials.gov (NCT03891420) A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19. U.S. National Institutes of Health. | ||||
| 7 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. | ||||
| 8 | Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid-19 infection. April.21.2020. Doi: 10.31219/osf.io/urxwh | ||||
| 9 | Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020. | ||||
| 10 | Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. | ||||
| 11 | BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.